USA flag logo/image

An Official Website of the United States Government

Diffused Optical Tomography using Oxygen-sensitive Luminescent Contrast Agent…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85484
Program Year/Program:
2007 / STTR
Agency Tracking Number:
CA130518
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Radiation Monitoring Devices, Inc.
44 Hunt St. Watertown, MA 02472-4699
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: Diffused Optical Tomography using Oxygen-sensitive Luminescent Contrast Agent for
Agency: HHS
Contract: 1R41CA130518-01A1
Award Amount: $210,345.00
 

Abstract:

DESCRIPTION (provided by applicant): Molecule specific targeting and improving image contrast have been recognized as important research areas in cancer imaging. Goal of cancer diagnosis and prognosis research is to develop new imaging techniques to detect lesions with certainty in early stages so that they can be treated. Developing biomarkers, which will signal the presence and the type of lesion is a major thrust area in cancer imaging. Special emphasis is on developing biomarkers, which will predict the development of invasive and non-invasive cancer after treatment. In this work, we will focus on detecting and imaging hypoxic breast cancer using near-infrared (NIR) based diffused optical tomography (DOT) technique. Image contrast will be improved by usi ng contrast agents targeting specific cancer cells involved with vasculature growth. Persisting hypoxia in a growing tumor can cause changes in the cells leading to aggressive cancer phenotype. Hypoxia driven progression often leads to local invasive growt h, perifocal tumor cell spreading and distant cell tumor spreading. Similarly resistance to radiation and other treatments may become enhanced. Hence, it is necessary to monitor deep tissue hypoxic cancers, distinguish them from non-cancer specific hypoxia (i.e., due to physical injury etc.,) using a non-invasive imaging technique. Radiation Monitoring Devices, Inc (RMD) in collaboration with Dr. Raoul Kopelman from University of Michigan, will develop a near infrared (NIR) diffused optical tomography (DOT) instrument for breast cancer detection using peptide based luminescent contrast agent. The proposed contrast agent will target endothelial cells lining the vasculature or breast cancer cells. It will be localized within tumor and its luminescence intensit y and lifetime will be oxygen- sensitive. Because poor oxygenation (hypoxia), which is a common feature of locally advanced solid tumors, can be utilized as a biomarker, the proposed contrast agent will provide an efficient way to monitor cancerous tumors. In addition, to advance the sensitivity of existing DOT instruments and take advantage of this new family of dyes, improvements to the optical system are proposed which includes use of sensitive Geiger mode avalanche detectors (GPD) and use of correlation technique. Demonstrating three-dimensional optical imaging using fluorescent lifetime tomography with a suitable contrast agent will provide a baseline for the performance of the Phase II prototype.

Principal Investigator:

Rajan Gurjar

Business Contact:

Gerald Entine
gentine@rmdinc.com
Small Business Information at Submission:

RADIATION MONITORING DEVICES, INC.
44 Hunt Street Watertown, MA 02472

EIN/Tax ID: 042546395
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UNIVERSITY OF MICHIGAN
UNIVERSITY OF MICHIGAN
ANN ARBOR, MI 48109
RI Type: Nonprofit college or university